Showing results (331-340 of 396) with videos related to
Sort By:
Pageof 40
JCO Precision Oncology|April 13, 2023
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.JCO Precision Oncology|October 9, 2025
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol TAnne S Tsao, Zihe Song, Alan L Ho, et al.Nature Communications|July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumorsLei Guan, Bin Wu, Ting Li, et al.Nature Communications|October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortalityJesse Fajnzylber, James Regan, Kendyll Coxen, et al.Cancer Immunology Research|January 9, 2025
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor SpheroidsYi Sun, Luke Maggs, Apekshya Panda, et al.Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.Cancer Discovery|December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaRani Ojha, Nektaria M Leli, Angelique Onorati, et al.Pageof 40